Navigation Links
Tianyin Reports Record First Quarter Fiscal Year 2011 Financial Results
Date:11/10/2010

CHENGDU, China, Nov. 10, 2010 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals announced financial results for the first quarter of Fiscal Year 2011.

First quarter fiscal year 2011 ending September 30, 2010 financial highlights

  • 1Q FY2011 revenue increased 63.7% year over year to $22.0 million from $13.4 million a year earlier
  • 1Q FY2011 Operating income delivered $4.6 million, up 66.3% from $ 2.7 million a year earlier
  • Net Income increased 68.0% to $3.7 million, up from $2.2 million a year earlier
  • Earnings per share of $0.13 per basic share, or $0.12 per diluted share, up from $0.10 per basic share, or $0.08 per diluted share a year earlier, a gain of 54.4%  
  • Cash and equivalents totaled $26.9 million on September 30, 2010
  • Sichuan Jiangchuan Pharmaceutical Co., Ltd. ("Jiangchuan") macrolide facility construction progress on schedule: completion by yearend 2010

  • 1Q FY2011 Results1Q FY2010

    1Q FY2009

    YoY Sales

    $22.0 million

    $13.4 million

    +63.7% Gross Profit

    $10.8 million

    $7.1 million

    +53.2%Operating Income

    $4.6 million

    $2.7 million

    +66.3% Net Income

    $3.7 million

    $2.2 million

    +68.0% EPS (Diluted)

    $0.12

    $0.08

    +54.4% Diluted Shares

    29.9 million

    27.5 million

    +8.7%Sales for 1Q FY2011 was $22.0 million, up 63.7% vs. $13.4 million for 1Q FY2010. The sales growth was supported by the continuing channel expansion, market penetration and optimized usage of our expanded production facility.

    Revenues from our top selling products are listed as f
    '/>"/>

    SOURCE Tianyin Pharmaceutical Co., Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Tianyin Pharmaceutical Co., Inc. to Host First Quarter of Fiscal Year 2011 Earnings Conference Call on Thursday, November 11, 2010 at 9:00 a.m. ET
    2. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2010 Earnings Conference Call on Thursday, September 30, 2010 at 9:00 a.m. ET
    3. Tianyin Corporate Presentation Updated
    4. Tianyin To Attend ROTH Fall Conference at Maui, Hawaii From September 1 - September 6
    5. Tianyin Promotes its Flagship Product Portfolio at the 45th 2010 National New Special Drugs Trade Fair in July at Beijing
    6. Tianyin Pharmaceutical Co., Inc. to Host Third Fiscal Quarter 2010 Results Earnings Conference Call on Wednesday, May 12, 2010 at 9:00 a.m. ET
    7. Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
    8. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
    9. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products
    10. Tianyin Pharmaceutical co., Inc. Announces Record First Quarter 2010 Financial Results
    11. Tianyin Pharmaceutical, Co. Announces Cash Dividend to Common Shareholders - Record Date October 30, 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
    (Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
    (Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
    Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
    ... Public/Private Sector Strategies for America,s Health Care Future (PS2) ... its report detailing how the state can reduce its ... areas that conservatively would save Florida taxpayers up to ... to identify steps the state could take that would ...
    ... EXTON, Pa., March 29, 2011 ViroPharma Incorporated (Nasdaq: ... Phase 2 clinical study to evaluate the safety and ... of acute antibody-mediated rejection (AMR) in recipients of donor-specific ... double blind, placebo-controlled study will evaluate the safety, tolerability ...
    Cached Medicine Technology:Senate Receives Rx Blueprint Plan That Reduces Spending and Increases Quality 2ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR) 2ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR) 3ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR) 4ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR) 5
    (Date:4/24/2014)... New research led by a scientist at the University ... key element in the development of the nervous system ... of breast cancer., A research team, led by ... the Department of Biology at York, has studied how ... tumours. These channels are found in the membranes of ...
    (Date:4/23/2014)... April 24, 2014 Pregnant immigrants from Sub-Saharan ... increased monitoring during pregnancy, according to new research ... today in the British Journal of Obstetrics ... and eclampsia rates among immigrants and native-born women ... (Ontario), Denmark, Sweden, Spain (Catalonia and Valencia) and ...
    (Date:4/23/2014)... O,Shea, M.D., scientific director at the National Institute of ... named the 2014 recipient of the Ross Prize in ... journal Molecular Medicine . The award will be ... of Sciences in Manhattan, followed by scientific presentations by ... of the National Institutes of Health. , The award, ...
    (Date:4/23/2014)... Johns Hopkins scientists report that rats exposed to high-energy ... deep space mission, show lapses in attention and slower ... extremely low dose ranges. , The cognitive impairments ... of the animals appear to be linked to ... findings, if found to hold true in humans, suggest ...
    (Date:4/23/2014)... compound that targets an important brain receptor has a ... including relapse behavior, a University at Buffalo animal study ... this may be a novel lead compound for treating ... UB research was published as an online preview article ... study, the compound, RO5263397, severely blunted a broad range ...
    Breaking Medicine News(10 mins):Health News:Breast cancer replicates brain development process 2Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2
    ... she made her American debut at the side ... ViKY, as she is affectionately known, is a ... France. With ViKY at his side, Dr. Rosenfield ... laparoscopic hysterectomy in the world. Significantly, the entire ...
    ... surgery for athletes greatly reduces risk of recurring injury, ... -- Surgery to repair a young athlete,s dislocated shoulder ... to experts who looked at two types of shoulder ... , "Studies show that performing arthroscopic surgery to repair ...
    ... 2 GAC International ( www.gacintl.com ) announced today ... Mystique(R) MB. This second generation ceramic bracket ... system into the design, ensuring reliable bonding and debonding ... number of teens and adults seeking aesthetic treatment, now ...
    ... a special MRI technique, researchers have determined that the location ... sufferers can be markedly persistent over time. The findings will ... , "A considerable number of airways appeared to be ... E. de Lange, M.D., professor of radiology at the University ...
    ... first hip replacement fails, patients may be concerned that their ... the prognosis is poor. However, a research study to be ... Bone and Joint Surgery suggests that this may not ... Center examined their results using one of the first cementless ...
    ... of Salmonella , there are many questions. And answers ... start? Can it be contained? Is the sickness likely to ... for testing for the presence of Salmonella that ... by Byron Brehm-Stecher, assistant professor in food science and human ...
    Cached Medicine News:Health News:A World First in Minimally Invasive Robotic Surgery Promises a More Cost-Effective, Patiently Friendly Future 2Health News:A World First in Minimally Invasive Robotic Surgery Promises a More Cost-Effective, Patiently Friendly Future 3Health News:Quick Orthopedic Repair Can Save Young Shoulders 2Health News:GAC International Launches Mystique(R) MB Second Generation Ceramic Bracket 2Health News:Even with medication, asthma patients show chronic airflow changes in lungs 2Health News:Cementless cup device developed for hip replacements shows durability after more than 20 years 2Health News:ISU researchers develop technique for quick detection of Salmonella 2
    Manufacturer of the WellPro since 1992, ProGroup previously distributed the instrument through Denley and Labsystems. A direct replacement for the ProPette the WellPro performs serial dilutions in an...
    ... compatible with hood installations. ... system for 384-well plates, ... prepares large quantities of ... Wellpro also performs plate ...
    ... The Aquarius 384 is a ... Aquarius 384-well head is a unique ... washing using the included wash system. ... 250 microplate stacker system. Will ...
    ... new Nanopipetting System Genesis NPS based on ... allows you to miniaturize your assays for ... picking and direct dilutions., Furthermore it ... applications including gene expression analysis, gene mapping, ...
    Medicine Products: